Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10898497-B2
Publication Date
2021-01-26
Expiration Date
Abstract
Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies.
Core Innovation
The document describes autologous cartilage repair compositions and methods that combine platelet-based materials prepared from a patient with chondrogenesis inducing agents, and administer the resulting components to a site in need of cartilage repair. The platelet-based materials include platelet lysate, platelet-rich plasma, platelet-rich fibrin, and whole cell platelet concentrate, together with one or more chondrogenesis inducing agents intended to facilitate chondrogenesis and cartilage repair at the site.
In the described approach, autologous mesenchymal stem cells (MSCs) are obtained from the patient and administered with the platelet-based material and the chondrogenesis inducing agent(s). At least one of the chondrogenesis inducing agents is a corticosteroid, including dexamethasone, and additional examples include growth factors, cytokines, hormones, and nutrients.
The described compositions and methods also incorporate carrier materials such as gels, hydrogels, or foams and may include cell-based therapy options, including MSCs or chondrocytes, in addition to platelet-based materials and chondrogenesis inducing agents. The document describes therapeutic use in conditions such as osteoarthritis and defines autologous platelet lysate, including a quantitative range and preparation by freeze-thawing.
Claims Coverage
The provided claims content explicitly identifies one independent claim and several dependent refinements. The inventive features center on autologous platelet rich plasma, autologous MSCs from defined patient sources, administration with one or more chondrogenesis inducing agents to a cartilage repair site, and the requirement that at least one chondrogenesis inducing agent is a corticosteroid.
Autologous platelet rich plasma with autologous MSCs for cartilage repair
Preparing autologous platelet rich plasma; obtaining autologous mesenchymal stem cells (MSCs) from bone marrow, peripheral blood, or adipose tissue of the patient; and administering the MSCs, the autologous platelet rich plasma and one or more chondrogenesis inducing agents to a site in the patient in need of cartilage repair.
Corticosteroid chondrogenesis inducing agent requirement
Facilitating cartilage repair at the site in the patient in need of repair, where at least one of the chondrogenesis inducing agents is a corticosteroid.
Corticosteroid identified as dexamethasone
The corticosteroid is dexamethasone.
Platelet component variants including platelet rich fibrin, whole cell platelet concentrate, and 5% to 40% platelet lysate
Further administering platelet rich fibrin, whole cell platelet concentrate, or a 5% to 40% platelet lysate solution obtained via freeze-thawing, or a mixture, to the patient, with administration at the repair site.
Carrier material comprising gel, hydrogel, or foam
Administering a carrier material comprising a gel, hydrogel, or foam.
The claims collectively define cartilage repair by administering autologous MSCs with autologous platelet rich plasma and one or more chondrogenesis inducing agents to a cartilage repair site, with the added requirement that at least one chondrogenesis inducing agent is a corticosteroid. The refinements specify dexamethasone, platelet rich fibrin, whole cell platelet concentrate, a 5% to 40% platelet lysate range produced by freeze-thawing, and carrier materials such as gels, hydrogels, or foams.
Stated Advantages
Facilitates cartilage repair at the site in the patient in need of repair.
Documented Applications
Therapeutic use in conditions such as osteoarthritis.
Interested in licensing this patent?